British Columbia licensed cannabis producer Tilray is proud to support important safety and tolerability studies with the desired outcome of arming physicians and parents with significant dosing and tolerability data on a combination cannabinoid product for treatment of seizures in a pediatric population, and expanding the research knowledge base to inform future efficacy trials with formulations containing multiple cannabinoids. Read more: https://www.tilray.ca/en/blog/post/tilray-shares-update-pediatric-epilepsy-clinical-trial/
This first-of-its-kind pediatric epilepsy clinical trial is one of several research efforts underway at Tilray, a global leader in medical cannabis research, production and cultivation. Earlier this year, Tilray announced two additional ground-breaking clinical research collaborations: Canadas first clinical trial to evaluate the therapeutic potential of medical cannabis as treatment for symptoms associated with post-traumatic stress disorder (PTSD) in partnership with the University of British Columbia, as well as a partnership in Australia with the New South Wales (NSW) Government, the University of Sydney and Chris O`Brien Lifehouse to develop a novel medical cannabis treatment for chemotherapy-induced nausea and vomiting (CINV). In the coming months, the company is poised to announce additional scientific trials to continue examining the efficacy of medical cannabis treatment for a subset of medical conditions and diseases. The SickKids trial is expected to start in early 2017.
Tilray has been a strong advocate for insurance coverage of medical cannabis products, and we will continue to advocate for insurance coverage for all of our patients. It is our hope that this trial, if it demonstrates the effects of a specific medical cannabis product for a patient population with high need, will enhance our efforts to help patients get the insurance coverage they so desperately need to make medical cannabis products more accessible to them and their families. We also urge patients to contact their insurance providers to let them know why medical cannabis coverage is so important.